Nuvation Bio Inc. (NUVB)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$125.4M
Cash & Equivalents
$5.1M
Quarterly Burn Rate
$2,029M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
TALETRECTINIB ADIPATE
IBTROZI |
APPROVED | Advanced Breast Cancer, Advanced Breast Carcinoma, Advanced Solid Tumor, Astrocytoma, Grade IV, Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Breast Cancer, Breast Carcinoma, Breast Tumor, Bronchogenic Carcinoma, Cancer, Cancer of Breast, Cancer of Ovary, Cancer of Pancreas, Cancer of Prostate, Cancer of the Breast, Cancer of the Ovary, Cancer of the Pancreas, Cancer of the Prostate, Cancer, Therapy-Related, Carcinoma, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Neoplasms, Castration-resistant Prostate Cancer, Castration-Resistant Prostatic Cancer, Gene Fusion, Genetic Alteration, Glial Cell Tumors, Glioblastoma, Glioma, Glioma, Malignant, Glioma, Mixed, HER2-negative Breast Cancer, IDH1-mutant Glioma, Lung Diseases, Lung Neoplasms, Malignancies Multiple, Malignant Solid Tumor, Malignant Tumor of Breast, Metastatic Breast Cancer, Metastatic Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer (mCRPC), Molecular Sequenc |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-03-01 | Phase2 Readout | — |
Active Clinical Trials (7)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT04151342 | CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS) | OTHER | Recruiting | 5,500 |
| NCT05303519 | SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | PHASE3 | Recruiting | 365 |
| NCT06564324 | A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-smal... | PHASE3 | Recruiting | 194 |
| NCT07154706 | Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) | PHASE3 | Recruiting | 180 |
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | PHASE2 | Active Not Recruiting | 466 |
| NCT04395677 | A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene | PHASE2 | Active Not Recruiting | 173 |
| NCT04919811 | Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC | PHASE2 | Active Not Recruiting | 217 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-30 | 8-K | Nuvation Bio Inc. (NUVB) (CIK 0001811063) - EX-10.1 | EDGAR |